October 17, 2023
CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated recruitment and will enroll its first patient at UPMC Hillman Cancer Center,…